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ABSTRACTS 
A b s t r a c t s fo r O r a l S e s s i o n : 
HYPERTENSION 
1 2 . 1 3 . 
P r ev a l e n c e o f H y p e r t e n s i o n in t h e H o n g K o n g C a r d i o v a s c u l a r R i s k F a c t o r 
P r e v a l e n c e S t u d y C o h o r t 
B M Y C h e u n g , YB Man, NMS Wat, JLF Lo, DFY Chau, CY Law, T H Lam,1 GM 
Leung,1 SCF Tarn,2 C H Cheng , C R Kumana , CP Lau , K S L Lam . Unive r s i ty 
Depa r tmen t o f Med i c i n e , D e p a r t m e n t o f C o m m u n i t y Med ic ine ,1 T h e Un ive r s i t y o f 
Hong Kong; Clinical Biochemistry Unit,2 Queen Mary Hospi ta l , Hong Kong 
I n t r o d u c t i o n : In 1995-6 2 8 8 1 H o n g K o n g m e n a n d w o m e n a g e d 2 5 - 7 4 w e r e 
randomly cho sen t o par t ic ipa te in the H o n g K o n g Ca rd i ova s cu l a r R i sk Fac to r 
P r e v a l e n c e S t udy . H e r e w e r e p o r t t h e p r e v a l e n c e o f h y p e r t e n s i o n in s u b j e c t s r e c a l l e d 
for fo l low u p af ter 6 yea r s . 
Method s : 1046 subjects (506 men, 540 women ; age 52?12 yrs) were randomly 
chosen f rom the coho r t . B l o o d p r e s s u r e w a s m e a s u r e d ca r e fu l l y , a f t e r 5 m i n o f res t , 3 
t imes a t 5-min in te rva ls . Hype r t e n s i on w a s def ined as sys to l i c p r e s su r e o f > 140 m m H g 
and/or diastolic p re s su re o f > 90 m m H g , or i f h av ing med i c a t i o n to t r ea t hyper t ens ion . 
R e s u l t s : T h e p r e v a l e n c e o f h y p e r t e n s i o n in 1995 -6 a n d 2 0 0 1 - 2 is 1 8 . 0 % and 2 6 . 7 % 
respect ively (p<0 .001) . After adjus t ing for age , the p r eva l ence o f hyper t ens ion has 
increased by 15 .7%. In 2001 -2 , the p reva lence o f hype r t en s i on in > 6 4 years is 
5 3 . 8 + 4 . 9 % i n m e n a n d 5 2 . 3 ? 5 . 4 % i n w o m e n . 
Prevalence of hypertension in percentage. T h e n u m b e r o f s u b j e c t s is g i v e n in b r a ck e t s . 
Age <35 35-44 45-54 55-64 65-74 >74 
1995-6 Male 2.8(316) 6.6(395) 17(277) 3 7 . 3 ( 2 4 9 ) 5 1 . 9 ( 1 6 2 ) -
Female 0.6(310) 5.4(503) 2 0 . 2 ( 3 0 2 ) 4 0 . 4 ( 2 1 3 ) 5 4 . 5 ( 1 5 4 ) -
2001-2 Male 5.6(36) 13.4*(119) 23.8 (160) 42.5 (87) 54.8(84) 50(20) 
Female 0(29) 4.8(147) 19.1(194)48.8(84) 50.8(63) 56.5(23) 
* p < 0 . 0 5 v s . 1 9 9 5 - 6 
C o n c l u s i o n : T h e p r e v a l e n c e o f hype r t en s i on r i ses s h a r p l y w i t h ag e , e spec i a l l y af ter 
55 years o f age . T h e p r eva l ence o f hype r t ens ion in m a l e u n d e r 4 5 appea r s t o have 
doub led s ince t he las t survey. 
1 4 . 
A d v a n t a g e s o f b l o o d p r e s s u r e o p t i m i s a t i o n s t u d y 
B M Y Cheung, YB Man, HF Tse , CR Kumana, CP Lau 
Depa r tmen t o f Medic ine , Univers i ty o f H o n g K o n g , H o n g K o n g 
I n t r o d u c t i o n : Lowe r i ng b l ood p ressu re (BP) r e duc e s ca rd iovascu l a r even t s bu t 
agg re s s i ve B P con t ro l m a y n o t b e a d v a n t a g e o u s . O u r a i m w a s t o c o m p a r e op t imal B P 
control (<120/80 mmHg) with conventional BP targets (<140/90 mmHg) in hypertensive 
pat ients in t e rms o f t a rge t o rgan d a m a g e and to lerabi l i ty . 
M e t h o d : 23 hyper tens ive pa t ien ts (13 men and 10 w o m e n , age 4 7 ? 9 yrs) were 
r a n d o m i s e d t o o p t i m a l v e r s u s c o n v e n t i o n a l t r e a t m e n t f o r 6 m o n t h s . In i t i a l t h e r a p y w a s 
lercanidipine 10 m g daily. Fo r B P control, the dose could be doubled or other drugs 
added. W e s tudied three indices o f ta rget o rgan d a m a g e , left ven t r i cu la r ma s s index 
(LVMI), f low-mediated dilatation (FMD) o f the brachial artery and 24 hour urinary 
albumin excretion (UAE) . The coefficient o f var ia t ion o f L V M I and F M D 
m e a s u r e m e n t w e r e 7 % and 5 % respec t ive ly . 
R e s u l t s : B P dec r ea s ed s ign i f i can t ly by 2 1 . 3 ? 3 . 4 / 1 3 . 2 ? 1 . 7 m m H g in t h e conven t iona l 
g r oup and 26 . 6 ?3 . 6 / 17 . 9 ?1 . 5 m m H g in t he op t ima l g r o u p . Dias to l i c B P was 
significantly lower by 4 .7?2 .3 m m H g in the opt imal g r oup (p<0 .05) . Ambula tory BP 
also decreased s ignif icant ly in bo t h g roups . H e a r t r a t e d id n o t change s ignif icant ly in 
either group, The re were no significant changes in the L Y M , F M D or U A E in either 
g roup . H o w e v e r , b a s e l i n e L V M I and F M D w e r e r e l a t ed t o sy s to l i c B P ( f = 0 . 5 1 , p=0 . 02 
1*0.54, p = 0 . 0 0 9 ) , w h i l s t t h e c h a n g e i n u r i n a r y p r o t e i n e x c r e t i o n w a s r e l a t e d t o c h a n g e 
in t he sys to l i c B P ( r=0 . 52 , p = 0 . 0 2 ) . T r e a t m e n t w a s w e l l t o l e r a t ed , w i t h o u t any 
w i t h d r a w a l s . T h e r e w e r e n o s ign i f i can t d i f f e r ence s i n a d v e r s e e v e n t s b e t w e e n t h e 2 
g r o u p s . 
Conc lus ions : Optimisation o f BP using lercanidipine as initial therapy is feasible, 
safe and wel l to le ra ted . Howeve r , L V M and U A E did no t decrease , no r did endothel ial 
function improve in th is 6 mon th s tudy. 
EVALUATION OF EFFICACY AND TOLERABILITY OF A FIXED DOSE 
COMBINATION OF LOSARTAN AND RAMIPRIL IN THE MANAGEMENT OF 
HYPERTENSIVE PATIENTS WITH ASSOCIATED DIABETES MELLITUS 
L O R D T R I A L ( L O s a r t a n R a m i p r i l in Diabet ic Hype r t en s ive s ) 
D . P a w a r , S . R. J o s h i , M . E . Y e o l e k a r , K . K. Tr ipa th i , J . G i r i , A . K . M a i t y , M . Chopda , S. Maroli 
LTM Medica l Col lege and Genera l Hospi ta l , Mumba i , India 
A i m : T o eva lua te eff icacy a n d tolerabi l i ty o f comb ina t i on o f Losa r t an a n d Ramipr i l in the 
m a n a g e m e n t o f m i l d to m o d e r a t e hype r t ens ive pa t ien t s w i t h a s soc i a t ed d iabe tes mellitus.The 
s e c o n d a r y ob jec t ive w a s t o eva lua t e the e f f i cacy o f t h e c omb in a t i on in reducing 
m i c r o a l b u m i n u r i a . 
P a t i e n t s a n d M e t h o d s : T h e s tudy wa s an open , non - compa r a t i v e , mul t icent r ic clinical trial 
conduc ted in 7 centres in 325 pat ients . All the pat ients we r e t reated wi th Losar tan 50mg + 
Ramipril 2.5mg or Losartan 50mg + Ramipril 5mg once a day depending upon the baseline BP 12 
w e e k s . 
Resu l t s : The data wa s eva lua ted on a total o f 315 pat ien ts . T h e m e a n p res tudy systolic BP was 
160.56+ 14.44 which was s ignif icant ly reduced to 126.85 + 9.78 at the end of 12 weeks 
(PO.OOl) . Similarly the mean diastolic BP was 98.91 ? 8.33 at baseline which was significantly 
reduced to 79.82 ? 5.42 at the end o f 12 weeks (P< 0.001). A mean fall o f 33.72 mmHg and 
19 .10mm H g was observed in systolic and diastolic B P respect ive ly wh ich was statistically highly 
significant (PO.OOl) . The JTSTC-7 goal of blood pressure <130/80 was achieved in 79.05% 
pat ien ts . A t the end o f the t h e r apy 2 0 . 8 % pat ients ach ieved no rmoa l buminu r i a . 
Conc lus ion : The fixed dose combina t ion o f Losar tan and Ramip r i l s howed good to excellent 
efficacy response in 98 .10% patients and achieved a target b lood pressure o f 130/80 mm Hg in 
7 9 . 0 5 % pat ients and 9 8 . 4 1 % pat ients reported good to exce l len t to lerabi l i ty . The combination 
r educed the ur inary a lbumin excre t ion in major i ty o f t he pa t ien t s w i t h microalbuminur ia and 
p ro t e i nu r i a . 
1 5 . 
D i f f e r e n t e f fec t s o f l e r c a n i d i p i n e a n d f e l o d i p i n e o n c i r c a d i a n b l o o d p r e s s u r e a n d h e a r t ra te 
a m o n g h y p e r t e n s i v e p a t i e n t s 
B S P . F o k \ G. Co rne l i s s en2 , F. Halberg2, T T W . Chu3 , G N . Thomas4 , B . Tomiinson3. 
'Department of Anaesthesia & Intensive Care, * Department of Medicine and Therapeutics, The 
Chinese University of Hong Kong; 4Department of Community Medicine, The University of 
Hong Kong, Hong Kong. 2Chronobiology Laboratories, University of Minnesota, USA 
P u r p o s e : T h i s s t udy w a s c onduc t e d to compa r e the c h a n g e s in a v e r ag e a nd variabil i ty of 
ambulatory blood pressure (BP) and heart rate (HR) recordings with lercanidipine and felodipine 
t rea tment in Chinese patients with pr imary hypertension. 
M e t h o d s : After w i t hd r aw ing from their previous an t i -hyper tens ive medica t ion , 30 pat ients with 
p r ima ry hype r t en s i on w e r e r andomized to doub le -b l ind t r e a tmen t w i th l e rcan id ip ine lOmg once 
da i ly o r fe lodip ine E R 5 m g once dai ly after four week s o f p l a cebo run- in . T h e dosages were 
doub led after four week s if cl inic BP was not control led and t r ea tmen t con t inued for a total o f 12 
w e e k s . A m b u l a t o r y B P and H R w e r e recorded before and af ter t he act ive t r e a tmen t phase and 
b i o c h e m i c a l p a r a m e t e r s w e r e m o n i t o r e d . 
R e s u l t s : B o t h t r e a t m e n t s w e r e w e l l t o l e r a t ed a n d t h e r e w e r e n o t r e a t m e n t - r e l a t e d d rop -ou t s . 
Fi t ted c i rcadian var ia t ions in BP showed signif icant r educ t ions in t he mid l ine -es t ima t ing statistic 
of rhythm (MESOR) of systolic (S) BP and diastolic (D) BP with both lercanidipine (mean ? SE, 
-10.5 ? 3 . 0 / - 4 . 5 ? 1.4 m m H g , p<0 .01 ) and fe lodipine (-17.1 ? 2 .8/ -10.1 ? 1.6 m m Hg , p<0.001) . 
T h e ch ange s in M E S O R D B P we re greater wi th fe lod ip ine , bu t t h e pulse p re s su re w a s reduced 
(p<0 .02 ) t o s imi la r ex t en t by bo th t rea tments (-6.0 ? 2.2 m m H g fo r l e rcan id ip ine , -7 .0 ? 1,6 mm 
Hg for fe lodipine) . Reduc t ions in circadian ampl i tudes o f SBP and DBP we re no t significant 
wi th e i the r t rea tment . T h e M E S O R o f HR was increased (by 4.5 ? 1.7 bea t s /min , p<0 .02 ) among 
sub j ec t s t r ea ted wi th l e rcan id ip ine and the c i rcadian amp l i t ude o f H R w a s a l so increased (from 
15.7 ? 1.6 to 25.5 ? 2.4 beats /min , p<0.02) . Clinic BP and H R va lue s s howed s imi la r changes to 
the M E S O R va lues . The r e we r e no significant change s in p l a sma b iochemi s t r y or urine 
c a t e c h o l a m i n e s w i t h e i t h e r t r e a t m e n t . 
C o n c l u s i o n : Felodipine h ad a greater BP lowering effect than lercanidipine in these doses, 
espec ia l ly in reduc ing DBP . However , the increase in H R var iabi l i ty seen wi th lercanidipine 
m a y b e an addi t ional benefi t for hypertensive pat ients . 
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